Dale Schenk One Year Anniversary: Fighting to Preserve the Memories

Abstract

It has been a year since we lost Dale Schenk on September 30, 2016. Dale’s visionary work resulted in the remarkable discovery in 1999 that an experimental amyloid-β (Aβ) vaccine reduced the neurodegeneration in a transgenic model of Alzheimer’s disease (AD). Following Dale’s seminal work, several active and passive immunotherapies have since been developed and tested in the clinic for AD, Parkinson’s disease (PD), and other neurodegenerative disorders. Here we provide a brief overview of the current state of development of immunotherapy for AD, PD, and other neurodegenerative disorders in the context of this anniversary. The next steps in the development of immunotherapies will require combinatorial approaches mixing antibodies against various targets (e.g., Aβ, α-syn, Tau, and TDP43) with small molecules that block toxicity, aggregation, inflammation, and promote cell survival.

Keywords

Alzheimer’s disease immunotherapy Potamkin Prize synucleinopthy tauopathy

INTRODUCTION: DALE SCHENK A LIFE IN SCIENCE FIGHTING FOR THE CURE

It has been a year since we lost Dale Schenk on September 30, 2016 after a two-year battle with cancer. Dale belonged to that generation of scientists that heralded a new era on research and therapeutics for neurodegenerative disorders. But Dale was also a musician, loyal colleague, and a beloved friend and family man who, with an amazing sense of humor and enthusiasm, brought out the best in people. He was always kind, positive, and generous as a person and as a scientist.

He received his Bachelor’s degree in Biology in 1979 and his Doctorate degree in Pharmacology and Physiology from the University of California, San Diego (UCSD) in 1984. He first accepted a scientist position at Scios Inc. in California and in 1987 joined Athena Neurosciences in San Francisco, where he remained as Chief Scientific Officer when the company was acquired by Elan in 1996. At a time when there were only sporadic and limited interactions between industry and academic scientists, Athena Neurosciences, under Dale’s leadership, became the leader in the field at developing collaborations that led to remarkable discoveries in the fields of Alzheimer’s disease (AD) pathogenesis [1, 2], transgenic animal modeling [3 –6], and therapeutics for AD [7, 8] targeting amyloid-β protein precursor (AβPP) processing and amyloid-β (Aβ).

At this time, Dale’s visionary and innovative work resulted in the remarkable discovery in 1999 that an experimental Aβ vaccine reduced the accumulation of amyloid, neurodegeneration, and behavioral deficits in the PDAPP model of AD [1]. This work led to the testing of the first vaccine for AD targeting Aβ (AN1792) in humans. Although the Phase II clinical trial with this Aβ vaccine was stopped in 2002 due to the development of encephalitis in a handful of the patients [9, 10], Dale’s discovery propelled the field toward the new era of immunotherapy for neurodegenerative disorders for many years to come [11, 12]. Following Dale’s seminal work, several active and passive immunotherapies have since been developed and tested in the clinic for AD, Parkinson’s disease (PD), and other neurodegenerative disorders [13, 14]. Among many other honors, Dale was awarded in 2001 the American Academy of Neurology’s Potamkin Prize for his ground-breaking research in AD immunotherapeutics. Although Dale is best known for his work on immunotherapy, he was also working with his team at Elan (Fig. 1) at developing new therapeutics modulating β- and gamma-secretases [2 , 15–19] as well as other pathways relevant to AD and PD. Then, in 2009 Dale became the head of Elan’s newly formed company-Neotope Biosciences where he continued in conjunction with his colleagues and friends, Dora Games (Fig. 1) and Pete Seubert, and in collaboration with our group at UCSD the work on immunotherapy with a renewed interest in PD and other degenerative disorders of the aging population. Afterwards in 2012, Dale co-founded Prothena, a spin-off of Neotope Biosciences, where he continued the experimental and clinical development of the passive immunization for PD targeting α-synuclein (α-syn) (PRX002), as well as immunotherapy programs for systemic amyloid disorders such as AL amyloidosis (NEOD001) and ATTR amyloidosis (PRX004) and inflammatory disorders.

Fig.1

Dale with Elan and later on Prothena colleagues Kelly Wood-Johnson and Dora Games (Photo courtesy of Dr. Lisa McConlogue, friend and colleague of Dale).

Fifteen years after Dale’s discoveries harnessing the immune system to target Aβ for the treatment of AD, there are currently several active and passive immunization programs under development targeting α-syn for PD and multiple system atrophy (MSA); tau for AD and frontotemporal dementia (FTD); TDP-43 for FTD; Htt for Huntington’s disease; and PrPsc for Creutzfeldt-Jakob disease among others. In the next sections, we will provide a brief overview of the current state of development of immunotherapy for AD and Lewy body disease (LBD).

NEW HOPE FOR FINDING TREATMENTS FOR NEURODEGENERATIVE DISORDERS

AD [20], LBD [21], and FTD [22] are incurable neurodegenerative disorders of the aging population characterized by the progressive accumulation of misfolded protein aggregates (e.g., Aβ, α-syn, tau, TDP-43) that initially trigger synaptic damage and network dysfunction, and that eventually lead to loss of selected neuronal populations [23, 24]. Clinically they are characterized by cognitive impairment and memory loss (progressing to dementia), behavioral alterations and motoric dysfunction [20], and LBD [21]. Prior to Dale’s work on immunotherapy in the late 1990s, there were very few or no disease modifying experimental therapies considered or under clinical testing for neurodegenerative disorders; now there are dozens of clinical trials testing immunotherapy targeting Aβ, α-syn, and tau.

Dementing neurodegenerative disorders are the cause of suffering for patients and caregivers; AD is currently considered a major medical problem affecting over 5 million in the US, and close to 35 million people worldwide with numbers projected to rise to 115 million by 2050 [25, 26]. AD is the 6th cause of death in the US, and AD and related dementing disorders (ADRD) that include LBD, FTD, and vascular dementia, are the only top causes of death for which no prevention or cure is currently available [27]. For this reason, the US as well as other countries have developed National plans to address this public health emergency [28, 29]. In the US, on January 4, 2011, President Barack Obama signed into law the National Alzheimer’s Project Act (NAPA) (Public Law 111-375). The Act defines “Alzheimer’s” as AD and ADRD and calls as a major goal to accelerate the development of treatments that would prevent, halt, or reverse the course of AD/ADRD by the year 2025. The law also requests for: 1) the creation of National Plan that is updated yearly; 2) coordination of AD research and services across all federal agencies; 3) improved early diagnosis and coordination of care and treatment of AD; and 4) coordination with international bodies to fight AD globally (https://aspe.hhs.gov/national-alzheimers-project-act), among other activities. Moreover, the US Congress appropriated an additional $350 million dollars for Fiscal Year (FY) 2016 and $400 million dollars for FY2017 to the National Institute on Aging (NIA) to accelerate research on AD/ADRD. The NIA and its sister Institutes and Centers at the National Institutes of Health use the milestones and recommendations from the AD (2012 and 2015) and ADRD (2013 and 2016) Summits held at the NIH in Bethesda, MD, to prioritize areas of research for support.

While in AD, Aβ and tau accumulate in various cortical regions [30], in LBD, which is an heterogeneous group of disorders that includes PD, PD dementia (PDD), and dementia with Lewy bodies (DLB) [31 –33], the synaptic protein α-syn accumulates in cortical and subcortical nuclei [34, 35]. LBD in combination with other disorders with α-syn accumulation, such as MSA, are jointly referred to as synucleinopathies [36 –38]. In FTD, aggregates of either tau, TDP-43, or Fused in sarcoma (FUS) are found [39, 40]. Moreover, in FTD cases with the GGGGCC expansion mutation located in the intron 1 of the C9ORF72 gene, there is accumulation of TDP43 and repeat-associated non-ATG (RAN) translation proteins [41]) in the affected brain regions. Moreover, α-syn can accumulate in selected brain regions in AD [42] and that TDP-43 aggregates are found in the limbic system in AD and DLB [43]. These findings reinforce the idea that abnormal protein accumulation is key in most neurodegenerative disorders.

Aβ is well known to be secreted and to accumulate extracellularly [44], while α-syn, tau, and TDP-43 accumulate primarily intracellularly [45]. However, recent evidence has shown that aggregates of these proteins can be secreted [46 –48] and transmit from cell to cell both in neuronal and non-neuronal cells [48 –51]. This is important because the extracellular protein aggregates can be targeted with antibodies (Fig. 2). Under normal conditions most of these proteins can be found as soluble monomers in the cytoplasm or as dimers or tetramers associated with the plasma membrane [52 –54]. However, under pathological situations such as those characterizing AD, LBD, and FTD, various forms of these protein arrays including small oligomers, larger oligomers, protofibrils, and fibrils [55 –59] can be detected both intracellularly and as well as in the extracellular environment where it can transmit from cell to cell [60 –65], providing a strong rationale for the development of immunotherapeutic approaches for AD, LDB, and FTD (Fig. 2).

Fig.2

Mechanisms of action of immunotherapy. Antibodies against Aβ, tau, and α-syn work via multiple mechanisms including targeting aggregates in the membrane, reducing oligomerization and fibrillization, enhancing clearance via autophagy, ESCRT and microglia, preventing cell-to-cell propagation, reducing neuro-inflammation, and promoting neuronal survival.

Examples of immunotherapy under consideration for AD, LBD, and FTD includes, active, passive and T cell based approaches. Active immunization (or vaccination) seeks to promote the immune system (self) to generate antibodies against target proteins such as Aβ, α-syn, tau, and TDP-43, while in passive immunization pre-prepared antibodies against these proteins are administered (Fig. 2; Table 1). A different type of immunotherapy involves the activation of T cells that are able to modulate inflammatory responses; this approach has also been investigated for AD and PD [66, 67] (Fig. 2). While the upside is that antibodies can be designed to target specific proteins and conformations of Aβ, tau, α-syn, or TDP-43 and have multiple mechanisms of action [68 –73], the downside is the potential for non-specific inflammatory or immune reactions and limited penetration into the CNS. Active and passive immunization strategies are being explored in several clinical trials for AD and synucleinopathies (Table 1). Cellular immunization with activation of modulation of cells are under consideration for AD [74] and PD [75] although they are at earlier stage of development compared to antibody therapy.

Table 1

Examples of immunotherapy clinical trials for AD, tauopathies, and α-synucleinopathies

Target	Vaccine type	Compound/Epitope	Phase	Company	Disease application
Aβ	Active	ACI-24/N-term	I/II	AC Immune	AD and DS
		Lu AF20513/N-term	I	Lundbeck	Mild AD
Aβ	Passive	BAN2401/protofibril	II	Eisai	Mild AD
		Aduncanumab/oligos, fibrils	II	Biogen	Early AD
		Crenezumab/oligos, fibrils	II	Genetech	Preclinical AD
		Gantenerumab/oligos, fibrils	III	Hoffman-La Roche	Mild AD
		Solanezumab/N-term, soluble	III	Eli Lilly	Preclinical, mild AD
Tau	Active	ACI-35/4RTau, pS396, pS404	I	AC Immune	AD
		AADvac-1/4Tau, mid section	I	Axon Neuroscience	AD, FTD
Tau	Passive	BMS-986168/4RTau	I	Bristol-Myers squibb	AD
		RG7345/4Rtau, pTau	I	Hoffman-La Roche	AD
α-syn	Active	AFFIPD01A/c-term, oligos	I/II	AFFiRiS	PD
		AFFIPD03A/c-term, oligos	I/II	AFFiRiS	MSA
α-syn	Passive	PRX002/c-term, oligos	I/II	Prothena	PD
		BIIB054/conformational	I	Biogen	PD

AD, Alzheimer’s disease; DS, Down syndrome; FTD, frontotemporal dementia; PD, Parkinson’s disease; MSA, multiple system atrophy.

IMMUNOTHERAPY FOR AD AND TAUOPATHIES

The main targets for immunotherapy in AD are Aβ and tau, although recent studies have shown that α-syn [76] and TDP-43 [43 , 78] also participate in some aspects of AD and as such are potential targets as well. In addition to AD, tau also accumulates in other neurodegenerative disorders such as progressive supranuclear palsy, Pick’s disease, cortico-basal degeneration, and FTLD-14. The most developed clinical studies are those on Aβ immunotherapy, for which at least two active immunization and five passive immunization trials are currently undergoing. For tauopathies, two vaccines and three antibodies are currently in Phase I studies (Table 1). For α-syn, there are two active immunization and one passive immunization trials that have completed Phase I and are now moving toward Phase II; these clinical studies are centered at PD and MSA (Table 1). Moreover, there is one immunotherapy trial targeting the AD pathology in Down syndrome.

As described in previous sections, in the late 1990s Dale pioneered using immunotherapy for neurodegenerative disorders and in particular AD. As a result of his work, Dale developed an active immunization approach by vaccinating APP transgenic (tg) mice with Aβ_1 - 42 (AN-1792) and adjuvant [1]. Clinical trials in patients with mild to moderate AD with AN-1792 (full length Aβ_1 - 42) highlighted the risk of autoimmune responses when using this type of therapeutic strategy, as 6% of the patients in that study suffered with meningoencephalitis associated with T cell infiltration [79]. However neuropathological studies showed a considerable removal of amyloid in various brain regions [7, 80]. Current vaccines under development for AD includes CAD106 [81], Vanutide cridificar [82], and AD02 (AFFITOPE^®) [83]. Unfortunately, patients with mild to moderate AD treated with AD02, a synthetic peptide that mimics the N-terminus structure of the Aβ peptide, did not showed significant improvements. The CAD106 vaccine contains an Aβ_1–6 fragment as the immunogenic sequence attached to a carrier formed from the coat protein of bacteriophage Qβ as an adjuvant [15]. Phase II trials with CAD106 showed a good antibody response in AD patients with no side effects [26]; however, the study did not show clinical efficacy in patients with mild to moderate AD. Other active immunization trials against Aβ (Table 1) includes Lu AF20513 which consists of three repetitions of a modified Aβ_1 - 12 sequence in which the natural T helper cell epitopes are engineered to reduce the possibility of inducing harmful autoreactive T cell responses and to improve the ability to mount an effective immune response [84]. ACI-24 (Europe, Phase I/II) is a liposome vaccine designed to elicit an antibody response against aggregated Aβ peptides without concomitant pro-inflammatory T cell activation [85, 86]. ACI-24 also improved novel object recognition without triggering pro-inflammatory responses [86]. Finally, with support from NIA, Phase I vaccination trials with ACI-24 are currently been conducted in adult patients with Down syndrome which are known to develop AD. The study is assessing safety, tolerability, and immunogenicity in patients aged 35–55 years. This study was developed following experimental studies in a mouse trisomy model [87].

Because of the limited effects observed with active immunization against Aβ, other immunotherapy approaches have been developed including passive immunization with antibodies targeting specific epitopes or conformations of Aβ. Early studies by Solomon and her group showed that monoclonal antibodies against Aβ reduce fibrillation in vitro. Moreover, Dale as well as other groups developed and tested in vivo antibodies against the N-terminus of Aβ [5 , 90]. In this respect, his group showed that the monoclonal antibody 3D6 (which binds to deposited amyloid plaques and promotes clearance of Aβ) displayed efficacy in PDAPP mice [3, 5]. The humanized monoclonal antibody counterpart bapineuzumab, directed against the Aβ N-terminus (Aβ_1–5), showed some initial promise in Phase II trials; however, subsequent parallel-group Phase III trials did not confirm the efficacy of this antibody in ameliorating the cognitive impairment in patients with AD while at the same time displaying adverse effects such as vasogenic edema [15, 27]. Interestingly, PET studies showed a reduction in Aβ accumulation in the brains of patients treated with bapinezumab (N-terminus) [91 –93].

Other passive immunization approaches using monoclonal antibodies against Aβ_1 - 40 [94], Aβ_1 - 42 [3], pyroglutamate Aβ [95], oligomers [96], or protofibrils [97 –99] have also been developed and tested in vivo. Currently, clinical trials with the antibodies BAN2401 (protofibrils) [100], crenezumab (aggregated species) [101], gantenerumab (fibrils) [102 –104], and solanezumab (soluble Aβ mid-domain) [105, 106] are undergoing or have been completed (Table 1). Among them, clinical trials with solanezumab—an antibody that binds soluble Aβ systemically and probably works via a “sink” mechanism has completed Phase III in patients with mild to moderate AD. Although the primary end points were not attained in these trials, post hoc analysis showed a potential beneficial effect in patients with mild AD; subsequent studies confirmed a modest effect in cognitive scores that was not significant [107, 108]. Finally, recent studies with aducanumab (BIIB037), a monoclonal antibody binding to aggregated Aβ and derived from healthy aged donors, showed a dose-dependent (1, 3, and 10 mg/kg) reduction in amyloid deposition in six cortical regions of the brain. In a Phase II trial in 166 patients with early AD, aducanumab showed a dose dependent improvement in cognitive performance [109]. The reasons for the limited effects of passive immunization against Aβ in patients with AD are still under investigation; however, there are a number of possible pitfalls that have been proposed including: poor penetration of the antibodies, questions about antibody specificity, selecting the wrong target, insufficient Aβ reduction, or the immunotherapy should have been started earlier before substantial amyloid deposition in the brains of patients with AD occurred (too late). In fact, most of the studies described above were undertaken in patients with mild to moderate AD at a time when considerable amounts of amyloid have deposited in the brain. This emphasizes the need for clinical trials targeting earlier stages of the disease, that is primary or secondary prevention trials. In this regard and with NIA support, both solanezumab and gantenerumab are currently being tested for prevention of AD in individuals carrying autosome-dominant AD-causing mutations (adult children of parents with the familial form of the disease) as part of the Dominantly Inherited Alzheimer’s Network (DIAN) study which builds upon the results of earlier studies, suggesting effective antibody treatment of early-stage AD [15, 28]. Moreover and with NIA support, crenezumab has been investigated in a prevention trial as part of the Alzheimer Prevention Initiative (API) in individuals in the Medellin, Colombia area carrying the Presenilin 1 mutation (PS1) for which Aβ accumulation can be detected by biomarkers at around 25 years of age [15 , 111]. Finally, another prevention trial is the so-called A4 study that is being conducted in older individuals who have evidence of amyloid plaque build-up in their brains and who may be at risk for memory loss and cognitive decline due to AD. The A4 study is testing the effects of solanezumab in older individuals, who do not yet show symptoms of AD clinically, with the aim of slowing memory and cognitive decline. The A4 study will also test whether solanezumab treatment can delay the progression of amyloid deposition in the brain by imaging and other biomarkers [112].

In AD and other neurodegenerative disorders of the aging population, tau accumulates in the brain [113 –118]. Since cognitive alterations correlate with tau pathology [119, 120], removing tau has become a priority in AD and FTD [121, 122]. Both vaccination with tau antigens and immunization with monoclonal antibodies against tau have reduced accumulation and diminished behavioral deficits in tg mouse models of tauopathy [122 –129]. Vaccination utilizing phosphorylated tau epitopes [123, 129] has displayed encouraging results in animal models, and two tau vaccines are currently in Phase I trial for AD, AADvac-1, and ACI-35 (Table 1). AADvac-1 consists of a synthetic peptide derived from amino acids 294 to 305 of the tau sequence, although the precise molecular nature of the antigen has not been disclosed. ACI-35 is a liposome-based vaccine that elicits an immune response against pathological conformers of phosphorylated tau without mounting autoimmune B cell or T cell responses against physiological tau conformations. The resulting antibodies bound pathological tau in the brain [130]. Passive immunization with anti-phospho-tau antibodies reduce tau pathology and functional deficits [124 , 131–133], and antibodies targeting tau oligomers have also showed promise in tg models [123, 134], including a concomitant upstream reduction in Aβ pathology [135]. In this sense, there are 3 anti-tau antibodies currently being studied in Phase I trials (Table 1). BMS-986168 targets extracellular, N-terminally fragmented forms of tau (eTau). Finally, the recombinant humanized anti-tau antibody C2N-8E12 has recently begun a Phase I clinical study in patients with progressive supranuclear palsy.

Together, these studies suggest that passive immunization against Aβ and tau might hold promise for disease modification at earlier stages of AD, however more research is needed.

IMMUNOTHERAPY FOR SYNUCLEINOPATHIES

α-Syn is a small 140 amino acid long synaptic protein involved in synaptic transmission and vesicle release [136] that was initially identified in AD brains associated with plaque formation and neurodegeneration [137, 138] and in Lewy bodies (LBs) in PD [139]. Abnormal aggregation and accumulation of α-syn in synapses, axons, and in the neuronal cytoplasm as LBs are observed in PD and other synucleinopathies [55, 140], and therefore inhibiting α-syn aggregation would be a key mechanism for preventing its toxicity.

The first α-syn immunotherapeutic vaccine was a collaborative effort between our group at UCSD and Dale’s group at Elan, for these studies we used full length human α-syn protein and Freund adjuvant [141]. In these studies, α-syn aggregates and neurodegeneration were decreased in the α-syn tg mouse model of LBD, and antibodies isolated from the immunized mice promoted the degradation of α-syn aggregates [141]. Other active immunization approaches include using AFFITOPEs^®, which mimic abnormal conformations of α-syn, have been studied in animal models of PD and MSA [72, 73]. Vaccination with the AFFITOPEs^® AFF1 reduced neurodegeneration and improved motor and memory deficits in two α-syn tg models [73] and in a tg mouse model of MSA [72] and led to Phase I clinical trials with the AFFITOPEs^® PD01A and PD03A for PD and MSA.

Passive immunization approaches are also being pursued using antibodies against α-syn. Antibodies that recognize a C-terminus epitope of α-syn cleared intracellular aggregates, inhibited α-syn propagation and prevented C-terminus cleavage of the protein that may lead to increased aggregation [12 , 143]. Antibodies against the N-terminus were also effective at clearing α-syn aggregates, reducing their propagation and diminishing motor dysfunctions [144, 145]. Together, these reports support the value of immunotherapy with antibodies directed against α-syn for PD, and in this sense the C-terminus antibody PRX002 is currently the focus of a Phase I clinical trial (Table 1).

Since passive immunization uses immunoglobulins, which are voluminous proteins that do not easily cross the BBB and recognize a limited variety of epitopes, recent strategies have focused on using single chain antibodies (single chain variable fragment, scFv). scFvs retain antigen-binding properties and can be easily screened using phage display methodology. Using this approach, scFvs have been identified [146 –148] that detect individual conformational species of α-syn and could be potentially used to discriminate among “strains” [149] to treat different synucleinopathies or for diagnostic purposes. scFvs have been further modified with the LDL domain of apolipoprotein B to increase BBB penetrability and facilitate the clearance of α-syn in a tg model of DLB. The brain-targeted fusion antibody easily crossed the BBB and was internalized by neurons using the ESCRT pathway for enhanced degradation of α-syn aggregates [146], thus attenuating neuronal degeneration in vivo. The use of gene therapy with intracellular scFv (intrabodies) is also being explored for the detection and clearance of intracellular α-syn aggregates [150 –152].

Therefore, antibodies against α-syn ameliorate α-syn pathology by multiple mechanisms (Fig. 2) including reducing oligomerization and fibrillization [73 , 154]. Furthermore, antibodies may also facilitate clearance of extracellular α-syn and prevent cell-to-cell propagation [49 , 144], inflammation and promote cell survival. Importantly, both aggregation and cell-to-cell propagation are intimately related to α-syn toxicity and inflammation PD pathology, suggesting that these processes are promising therapeutic targets for immunotherapy. Likewise, cellular immunotherapy strategies are been developed for PD utilizing compounds such as copaxone that might block migration of cytotoxic T cells [75], although they are at earlier stage of development compared to antibody therapy. Future studies are investigating combination therapies with antibodies and T-cell mediated immunity.

CONCLUSIONS

In summary, immunotherapy strategies have been developed for AD, tauopathies, and α-synucleinopathies that are now at various stages of clinical development. The most advanced trials are those targeting Aβ; it is expected that by 2019 preliminary results might be available for the secondary prevention trials. Antibodies against Aβ, tau, and α-syn work via multiple mechanisms (Fig. 2) including reducing oligomerization and fibrillization, enhancing clearance via autophagy, ESCRT and microglia, preventing cell-to-cell propagation, reducing neuro-inflammation, and promoting neuronal survival. Next phase in the development of immunotherapies will require combinatorial approaches mixing for example antibodies against various targets (e.g., Aβ, α-syn, Tau) with small molecules that block toxicity, aggregation, and inflammation and promote cell survival [14, 155].

DISCLOSURE STATEMENT

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/17-1071).

References

Schenk

, Barbour

, Dunn

, Gordon

, Grajeda

, Guido

, Hu

, Huang

, Johnson-Wood

, Khan

, Kholodenko

, Lee

, Liao

, Lieberburg

, Motter

, Mutter

, Soriano

, Shopp

, Vasquez

, Vandevert

, Walker

, Wogulis

, Yednock

, Games

, Seubert

(1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177.

Sinha

, Anderson

, Barbour

, Basi

, Caccavello

, Davis

, Doan

, Dovey

, Frigon

, Hong

, Jacobson-Croak

, Jewett

, Keim

, Knops

, Lieberburg

, Power

, Tan

, Tatsuno

, Tung

, Schenk

, Seubert

, Suomensaari

, Wang

, Walker

, John

(1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537–540.

Bard

, Cannon

, Barbour

, Burke

, Games

, Grajeda

, Guido

, Hu

, Huang

, Johnson-Wood

, Khan

, Kholodenko

, Lee

, Lieberburg

, Motter

, Nguyen

, Soriano

, Vasquez

, Weiss

, Welch

, Seubert

, Schenk

, Yednock

(2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916–919.

Games

, Bard

, Grajeda

, Guido

, Khan

, Soriano

, Vasquez

, Wehner

, Johnson-Wood

, Yednock

, Seubert

, Schenk

(2000) Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42. Ann N Y Acad Sci 920, 274–284.

Bard

, Barbour

, Cannon

, Carretto

, Fox

, Games

, Guido

, Hoenow

, Hu

, Johnson-Wood

, Khan

, Kholodenko

, Lee

, Motter

, Nguyen

, Reed

, Schenk

, Tang

, Vasquez

, Seubert

, Yednock

(2003) Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A 100, 2023–2028.

Roberds

, Anderson

, Basi

, Bienkowski

, Branstetter

, Chen

, Freedman

, Frigon

, Games

, Hu

, Johnson-Wood

, Kappenman

, Kawabe

, Kola

, Kuehn

, Lee

, Liu

, Motter

, Nichols

, Power

, Robertson

, Schenk

, Schoor

, Shopp

, Shuck

, Sinha

, Svensson

, Tatsuno

, Tintrup

, Wijsman

, Wright

, McConlogue

(2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: Imlications for Alzheimer’s disease therapeutics. Hum Mol Genet 10, 1317–1324.

Nicoll

, Barton

, Boche

, Neal

, Ferrer

, Thompson

, Vlachouli

, Wilkinson

, Bayer

, Games

, Seubert

, Schenk

, Holmes

(2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65, 1040–1048.

Rinne

, Brooks

, Rossor

, Fox

, Bullock

, Klunk

, Mathis

, Blennow

, Barakos

, Okello

, Rodriguez Martinez de Liano

, Liu

, Koller

, Gregg

, Schenk

, Black

, Grundman

(2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9, 363–372.

Check

(2002) Nerve inflammation halts trial for Alzheimer’s drug. Nature 415, 462.

10.

Robinson

, Bishop

, Lee

, Munch

(2004) Lessons from the AN 1792 Alzheimer vaccine: Lest we forget. Neurobiol Aging 25, 609–615.

11.

Brody

, Holtzman

(2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31, 175–193.

12.

Valera

, Masliah

(2013) Immunotherapy for neurodegenerative diseases: Focus on alpha-synucleinopathies. Pharmacol Ther 138, 311–322.

13.

Bergstrom

, Kallunki

, Fog

(2016) Development of passive immunotherapies for synucleinopathies. Mov Disord 31, 203–213.

14.

Valera

, Spencer

, Masliah

(2016) Immunotherapeutic approaches targeting amyloid-beta, alpha-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics 13, 179–189.

15.

Citron

, Westaway

, Xia

, Carlson

, Diehl

, Levesque

, Johnson-Wood

, Lee

, Seubert

, Davis

, Kholodenko

, Motter

, Sherrington

, Perry

, Yao

, Strome

, Lieberburg

, Rommens

, Kim

, Schenk

, Fraser

, St George Hyslop

, Selkoe

(1997) Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3, 67–72.

16.

Haass

, Lemere

, Capell

, Citron

, Seubert

, Schenk

, Lannfelt

, Selkoe

(1995) The Swedish mutation causes early-onset Alzheimer’s disease by beta-secretase cleavage within the secretory pathway. Nat Med 1, 1291–1296.

17.

Liebscher

, Page

, Kafer

, Winkler

, Quinn

, Goldbach

, Brigham

, Quincy

, Basi

, Schenk

, Steiner

, Bonhoeffer

, Haass

, Meyer-Luehmann

, Hubener

(2014) Chronic gamma-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures. Mol Psychiatry 19, 937–946.

18.

Ren

, Schenk

, Basi

, Shapiro

(2007) Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. J Biol Chem 282, 35350–35360.

19.

Schenk

, Games

, Seubert

(2001) Potential treatment opportunities for Alzheimer’s disease through inhibition of secretases and Abeta immunization. J Mol Neurosci 17, 259–267.

20.

Pierce

, Bullain

, Kawas

(2017) Late-onset Alzheimer disease. Neurol Clin 35, 283–293.

21.

Galasko

(2017) Lewy body disorders. Neurol Clin 35, 325–338.

22.

Olney

, Spina

, Miller

(2017) Frontotemporal dementia. Neurol Clin 35, 339–374.

23.

Selkoe

(2004) Cell biology of protein misfolding: The examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol 6, 1054–1061.

24.

Taylor

, Hardy

, Fischbeck

(2002) Toxic proteins in neurodegenerative disease. Science 296, 1991–1995.

25.

Prince

, Bryce

, Albanese

, Wimo

, Ribeiro

, Ferri

(2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 9, 63–75e62.

26.

Alzheimer’s Association (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement 12, 459–509.

27.

Alzheimer’s Association (2013) 2013 Alzheimer’s disease facts and figures. Alzheimers Dementia 9, 1–71.

28.

SECRETARYOOTA, EVALUATION FPA, National Plan to Address Alzheimer’s Disease, https://aspe.hhs.gov/national-plans-address-alzheimers-disease-2016Plan, Accessed 9/12-2017.

29.

Alzheimer Disease International, National Alzheimer’s and dementia plans, https://www.alz.co.uk/dementiaplans/national-plans, Accessed 9/12-2017.

30.

Crews

, Masliah

(2010) Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet 19, R12–20.

31.

Donaghy

, McKeith

(2014) The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther 6, 46.

32.

McKeith

, Mintzer

, Aarsland

, Burn

, Chiu

, Cohen-Mansfield

, Dickson

, Dubois

, Duda

, Feldman

, Gauthier

, Halliday

, Lawlor

, Lippa

, Lopez

, Carlos Machado

, O’Brien

, Playfer

, Reid

, International Psychogeriatric Association Expert Meeting on DLB (2004) Dementia with Lewy bodies. Lancet Neurol 3, 19–28.

33.

McKeith

(2000) Spectrum of Parkinson’s disease, Parkinson’s dementia, and Lewy body dementia. Neurol Clin 18, 865–902.

34.

Goedert

, Jakes

, Anthony Crowther

, Grazia Spillantini

(2001) Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy as alpha-synucleinopathies. Methods Mol Med 62, 33–59.

35.

Spillantini

(1999) Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism Relat Disord 5, 157–162.

36.

Galvin

, Lee

, Trojanowski

(2001) Synucleinopathies: Clinical and pathological implications. Arch Neurol 58, 186–190.

37.

Spillantini

, Goedert

(2000) The alpha-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920, 16–27.

38.

Dickson

, Liu

, Hardy

, Farrer

, Mehta

, Uitti

, Mark

, Zimmerman

, Golbe

, Sage

, Sima

, D’Amato

, Albin

, Gilman

, Yen

(1999) Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 155, 1241–1251.

39.

Goedert

, Ghetti

, Spillantini

(2012) Frontotemporal dementia: Implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med 2, a006254.

40.

Ferrari

, Kapogiannis

, Huey

, Momeni

(2011) FTD and ALS: A tale of two diseases. Curr Alzheimer Res 8, 273–294.

41.

, Liu

, Banez-Coronel

, Reid

, Pletnikova

, Lewis

, Miller

, Harms

, Falchook

, Subramony

, Ostrow

, Rothstein

, Troncoso

, Ranum

(2013) RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A 110, E4968–4977.

42.

Winslow

, Moussaud

, Zhu

, Post

, Dickson

, Berezovska

, McLean

(2014) Convergence of pathology in dementia with Lewy bodies and Alzheimer’s disease: A role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain 137, 1958–1970.

43.

Arai

, Mackenzie

, Hasegawa

, Nonoka

, Niizato

, Tsuchiya

, Iritani

, Onaya

, Akiyama

(2009) Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol 117, 125–136.

44.

Glenner

, Wong

(1984) Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 12, 885–890.

45.

Bancher

, Brunner

, Lassmann

, Budka

, Jellinger

, Wiche

, Seitelberger

, Grundke-Iqbal

, Iqbal

, Wisniewski

(1989) Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain Res 477, 90–99.

46.

Danzer

, Krebs

, Wolff

, Birk

, Hengerer

(2009) Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem 111, 192–203.

47.

Masuda-Suzukake

, Nonaka

, Hosokawa

, Oikawa

, Arai

, Akiyama

, Mann

, Hasegawa

(2013) Prion-like spreading of pathological alpha-synuclein in brain. Brain 136, 1128–1138.

48.

Mohamed

, Herrou

, Plouffe

, Piperno

, Leclerc

(2013) Spreading of tau pathology in Alzheimer’s disease by cell-to-cell transmission. Eur J Neurosci 37, 1939–1948.

49.

Bae

, Lee

, Rockenstein

, Ho

, Park

, Yang

, Desplats

, Masliah

, Lee

(2012) Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32, 13454–13469.

50.

Lee

, Desplats

, Sigurdson

, Tsigelny

, Masliah

(2010) Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 6, 702–706.

51.

Smethurst

, Newcombe

, Troakes

, Simone

, Chen

, Patani

, Sidle

(2016) In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol Dis 96, 236–247.

52.

McLean

, Kawamata

, Ribich

, Hyman

(2000) Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson’s disease-linked mutations. J Biol Chem 275, 8812–8816.

53.

Bartels

, Choi

, Selkoe

(2011) alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107–110.

54.

Pooler

, Usardi

, Evans

, Philpott

, Noble

, Hanger

(2012) Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 33, 431e427–438.

55.

Lashuel

, Petre

, Wall

, Simon

, Nowak

, Walz

, Lansbury

Jr (2002) Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322, 1089–1102.

56.

Kayed

, Sokolov

, Edmonds

, McIntire

, Milton

, Hall

, Glabe

(2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279, 46363–46366.

57.

Hashimoto

, Rockenstein

, Crews

, Masliah

(2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromolecular Med 4, 21–36.

58.

Lasagna-Reeves

, Castillo-Carranza

, Sengupta

, Sarmiento

, Troncoso

, Jackson

, Kayed

(2012) Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J 26, 1946–1959.

59.

Lasagna-Reeves

, Sengupta

, Castillo-Carranza

, Gerson

, Guerrero-Munoz

, Troncoso

, Jackson

, Kayed

(2014) The formation of tau pore-like structures is prevalent and cell specific: Possible implications for the disease phenotypes. Acta Neuropathol Commun 2, 56.

60.

Kfoury

, Holmes

, Jiang

, Holtzman

, Diamond

(2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287, 19440–19451.

61.

Desplats

, Lee

, Bae

, Patrick

, Rockenstein

, Crews

, Spencer

, Masliah

, Lee

(2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106, 13010–13015.

62.

Angot

, Brundin

(2009) Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 3), S143–147.

63.

Danzer

, Haasen

, Karow

, Moussaud

, Habeck

, Giese

, Kretzschmar

, Hengerer

, Kostka

(2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27, 9220–9232.

64.

Jones

, Dubey

, Camp

, Vernon

, Biernat

, Mandelkow

, Majewski

, Chi

(2012) Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption. Biochemistry 51, 2539–2550.

65.

Lee

, Patel

, Lee

(2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25, 6016–6024.

66.

Reynolds

, Banerjee

, Liu

, Gendelman

, Mosley

(2007) Neuroprotective activities of CD4+CD25+regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol 82, 1083–1094.

67.

Reynolds

, Stone

, Hutter

, Benner

, Mosley

, Gendelman

(2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol 184, 2261–2271.

68.

Wang

, Das

, Switzer

, Golde

, Jankowsky

(2011) Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci 31, 4124–4136.

69.

Oddo

, Billings

, Kesslak

, Cribbs

, LaFerla

(2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321–332.

70.

, Congdon

, Sigurdsson

(2013) Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem 288, 33081–33095.

71.

Morgan

(2009) The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets 8, 7–15.

72.

Mandler

, Valera

, Rockenstein

, Mante

, Weninger

, Patrick

, Adame

, Schmidhuber

, Santic

, Schneeberger

, Schmidt

, Mattner

, Masliah

(2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 10, 10.

73.

Mandler

, Valera

, Rockenstein

, Weninger

, Patrick

, Adame

, Santic

, Meindl

, Vigl

, Smrzka

, Schneeberger

, Mattner

, Masliah

(2014) Next-generation active immunization approach for synucleinopathies: Implications for Parkinson’s disease clinical trials. Acta Neuropathol 127, 861–879.

74.

Monsonego

, Nemirovsky

, Harpaz

(2013) CD4 T cells in immunity and immunotherapy of Alzheimer’s disease. Immunology 139, 438–446.

75.

Hutter-Saunders

, Mosley

, Gendelman

(2011) Pathways towards an effective immunotherapy for Parkinson’s disease. Expert Rev Neurother 11, 1703–1715.

76.

Overk

, Cartier

, Shaked

, Rockenstein

, Ubhi

, Spencer

, Price

, Patrick

, Desplats

, Masliah

(2014) Hippocampal neuronal cells that accumulate alpha-synuclein fragments are more vulnerable to Abeta oligomer toxicity via mGluR5–implications for dementia with Lewy bodies. Mol Neurodegener 9, 18.

77.

Rohn

(2008) Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer’s disease. Brain Res 1228, 189–198.

78.

Uryu

, Nakashima-Yasuda

, Forman

, Kwong

, Clark

, Grossman

, Miller

, Kretzschmar

, Lee

, Trojanowski

, Neumann

(2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67, 555–564.

79.

Orgogozo

, Gilman

, Dartigues

, Laurent

, Puel

, Kirby

, Jouanny

, Dubois

, Eisner

, Flitman

, Michel

, Boada

, Frank

, Hock

(2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46–54.

80.

Nicoll

, Wilkinson

, Holmes

, Steart

, Markham

, Weller

(2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 9, 448–452.

81.

Wiessner

, Wiederhold

, Tissot

, Frey

, Danner

, Jacobson

, Jennings

, Luond

, Ortmann

, Reichwald

, Zurini

, Mir

, Bachmann

, Staufenbiel

(2011) The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31, 9323–9331.

82.

Arai

, Suzuki

, Yoshiyama

(2015) Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer’s disease: Results from two phase 2 studies. Curr Alzheimer Res 12, 242–254.

83.

Schneeberger

, Mandler

, Otawa

, Zauner

, Mattner

, Schmidt

(2009) Development of AFFITOPE vaccines for Alzheimer’s disease (AD)–from concept to clinical testing. J Nutr Health Aging 13, 264–267.

84.

Davtyan

, Ghochikyan

, Petrushina

, Hovakimyan

, Davtyan

, Poghosyan

, Marleau

, Movsesyan

, Kiyatkin

, Rasool

, Larsen

, Madsen

, Wegener

, Ditlevsen

, Cribbs

, Pedersen

, Agadjanyan

(2013) Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: Prelude to a clinical trial. J Neurosci 33, 4923–4934.

85.

Hickman

, Lopez-Deber

, Ndao

, Silva

, Nand

, Pihlgren

, Giriens

, Madani

, St-Pierre

, Karastaneva

, Nagel-Steger

, Willbold

, Riesner

, Nicolau

, Baldus

, Pfeifer

, Muhs

(2011) Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem 286, 13966–13976.

86.

Muhs

, Hickman

, Pihlgren

, Chuard

, Giriens

, Meerschman

, van der Auwera

, van Leuven

, Sugawara

, Weingertner

, Bechinger

, Greferath

, Kolonko

, Nagel-Steger

, Riesner

, Brady

, Pfeifer

, Nicolau

(2007) Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A 104, 9810–9815.

87.

Belichenko

, Madani

, Rey-Bellet

, Pihlgren

, Becker

, Plassard

, Vuillermot

, Giriens

, Nosheny

, Kleschevnikov

, Valletta

, Bengtsson

, Linke

, Maloney

, Hickman

, Reis

, Granet

, Mlaki

, Lopez-Deber

, Do

, Singhal

, Masliah

, Pearn

, Pfeifer

, Muhs

, Mobley

(2016) An anti-beta-amyloid vaccine for treating cognitive deficits in a mouse model of Down syndrome. PLoS One 11, e0152471.

88.

Solomon

, Koppel

, Hanan

, Katzav

(1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 93, 452–455.

89.

, Lim

, Harris-White

, Yang

, Ambegaokar

, Ubeda

, Glabe

, Teter

, Frautschy

, Cole

(2006) Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 83, 374–384.

90.

Shankar

, Li

, Mehta

, Garcia-Munoz

, Shepardson

, Smith

, Brett

, Farrell

, Rowan

, Lemere

, Regan

, Walsh

, Sabatini

, Selkoe

(2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14, 837–842.

91.

Blennow

, Zetterberg

, Rinne

, Salloway

, Wei

, Black

, Grundman

, Liu

, Investigators ftA- (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69, 1002–1010.

92.

Vandenberghe

, Rinne

, Boada

, Katayama

, Scheltens

, Vellas

, Tuchman

, Gass

, Fiebach

, Hill

, Lobello

, Li

, McRae

, Lucas

, Evans

, Booth

, Luscan

, Wyman

, Hua

, Yang

, Brashear

, Black

, Bapineuzumab 3000, 3001 Clinical Study Investigators (2016) Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther 8, 18.

93.

Abushouk

, Elmaraezy

, Aglan

, Salama

, Fouda

, AlSafadi

(2017) Bapineuzumab for mild to moderate Alzheimer’s disease: A meta-analysis of randomized controlled trials. BMC Neurol 17, 66.

94.

McLaurin

, Cecal

, Kierstead

, Tian

, Phinney

, Manea

, French

, Lambermon

, Darabie

, Brown

, Janus

, Chishti

, Horne

, Westaway

, Fraser

, Mount

, Przybylski

, St George-Hyslop

(2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8, 1263–1269.

95.

Frost

, Liu

, Kleinschmidt

, Schilling

, Demuth

, Lemere

(2012) Passive immunization against pyroglutamate-3 amyloid-beta reduces plaque burden in Alzheimer-like transgenic mice: A pilot study. Neurodegener Dis 10, 265–270.

96.

Zhang

, He

, Wang

, Bao

, Pang

, Yin

, Hu

, Peng

, Sun

, Zheng

, Hou

, Hong

(2011) Administration of amyloid-beta42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice. J Alzheimers Dis 23, 551–561.

97.

Lord

, Gumucio

, Englund

, Sehlin

, Sundquist

, Soderberg

, Moller

, Gellerfors

, Lannfelt

, Pettersson

, Nilsson

(2009) An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s disease. Neurobiol Dis 36, 425–434.

98.

Englund

, Sehlin

, Johansson

, Nilsson

, Gellerfors

, Paulie

, Lannfelt

, Pettersson

(2007) Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 103, 334–345.

99.

Moreth

, Mavoungou

, Schindowski

(2013) Passive anti-amyloid immunotherapy in Alzheimer’s disease: What are the most promising targets? Immun Ageing 10, 18.

100.

Lannfelt

, Moller

, Basun

, Osswald

, Sehlin

, Satlin

, Logovinsky

, Gellerfors

(2014) Perspectives on future Alzheimer therapies: Amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimers Res Ther 6, 16.

101.

Adolfsson

, Pihlgren

, Toni

, Varisco

, Buccarello

, Antoniello

, Lohmann

, Piorkowska

, Gafner

, Atwal

, Maloney

, Chen

, Gogineni

, Weimer

, Mortensen

, Friesenhahn

, Ho

, Paul

, Pfeifer

, Muhs

, Watts

(2012) An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 32, 9677–9689.

102.

Bohrmann

, Baumann

, Benz

, Gerber

, Huber

, Knoflach

, Messer

, Oroszlan

, Rauchenberger

, Richter

, Rothe

, Urban

, Bardroff

, Winter

, Nordstedt

, Loetscher

(2012) Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 28, 49–69.

103.

Ostrowitzki

, Deptula

, Thurfjell

, Barkhof

, Bohrmann

, Brooks

, Klunk

, Ashford

, Yoo

, Xu

, Loetscher

, Santarelli

(2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69, 198–207.

104.

Panza

, Solfrizzi

, Imbimbo

, Giannini

, Santamato

, Seripa

, Logroscino

(2014) Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease. Expert Rev Neurother 14, 973–986.

105.

Farlow

, Arnold

, van Dyck

, Aisen

, Snider

, Porsteinsson

, Friedrich

, Dean

, Gonzales

, Sethuraman

, DeMattos

, Mohs

, Paul

, Siemers

(2012) Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement 8, 261–271.

106.

Siemers

, Friedrich

, Dean

, Gonzales

, Farlow

, Paul

, Demattos

(2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33, 67–73.

107.

Siemers

, Sundell

, Carlson

, Case

, Sethuraman

, Liu-Seifert

, Dowsett

, Pontecorvo

, Dean

, Demattos

(2016) Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement 12, 110–120.

108.

Doody

, Thomas

, Farlow

, Iwatsubo

, Vellas

, Joffe

, Kieburtz

, Raman

, Sun

, Aisen

, Siemers

, Liu-Seifert

, Mohs

, Alzheimer’s Disease Cooperative Study Steering C, Solanezumab Study Group (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370, 311–321.

109.

Sevigny

, Chiao

, Bussiere

, Weinreb

, Williams

, Maier

, Dunstan

, Salloway

, Chen

, Ling

, O’Gorman

, Qian

, Arastu

, Li

, Chollate

, Brennan

, Quintero-Monzon

, Scannevin

, Arnold

, Engber

, Rhodes

, Ferrero

, Hang

, Mikulskis

, Grimm

, Hock

, Nitsch

, Sandrock

(2016) The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature 537, 50–56.

110.

Hsu

, Marshall

(2017) Primary and secondary prevention trials in Alzheimer disease: Looking back, moving forward. Curr Alzheimer Res 14, 426–440.

111.

Chen

, Fleischer

, Ayutyanont

, Langbaum

, Caselli

, Quiroz

, Lopera

, Tariot

, Reiman

(2012) Brain imaging biomarkers for the Alzheimer’s Prevention Initiative. J Transl Med 10(Suppl 2), A28.

112.

Sperling

, Rentz

, Johnson

, Karlawish

, Donohue

, Salmon

, Aisen

(2014) The A4 study: Stopping AD before symptoms begin? Sci Transl Med 6, 228fs213.

113.

Grundke-Iqbal

, Iqbal

, Quinlan

, Tung

, Zaidi

, Wisniewski

(1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084–6089.

114.

Wolozin

, Pruchnicki

, Dickson

, Davies

(1986) A neuronal antigen in the brains of Alzheimer patients. Science 232, 648–650.

115.

Lee

, Otvos

, Schmidt

, Trojanowski

(1988) Alzheimer disease tangles share immunological similarities with multiphosphorylation repeats in the two large neurofilament proteins. Proc Natl Acad Sci U S A 85, 7384–7388.

116.

Iwatsubo

, Hasegawa

, Ihara

(1994) Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics. Acta Neuropathol 88, 129–136.

117.

Hampel

, Teipel

(2004) Total and phosphorylated tau proteins: Evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 17, 350–354.

118.

Mandelkow

, Mandelkow

(1993) Tau as a marker for Alzheimer’s disease. Trends Biochem Sci 18, 480–483.

119.

Arriagada

, Growdon

, Hedley-Whyte

, Hyman

(1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42, 631–639.

120.

Bierer

, Hof

, Purohit

, Carlin

, Schmeidler

, Davis

, Perl

(1995) Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Arch Neurol 52, 81–88.

121.

Götz

, Ittner

(2012) Tau-targeted treatment strategies in Alzheimer’s disease. Br J Pharmacol 165, 1246–1259.

122.

Lasagna-Reeves

, Castillo-Carranza

, Jackson

, Kayed

(2011) Tau oligomers as potential targets for immunotherapy for Alzheimer’s disease and tauopathies. Curr Alzheimer Res 8, 659–665.

123.

Asuni

, Boutajangout

, Quartermain

, Sigurdsson

(2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27, 9115–9129.

124.

Boutajangout

, Ingadottir

, Davies

, Sigurdsson

(2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118, 658–667.

125.

Boutajangout

, Quartermain

, Sigurdsson

(2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30, 16559–16566.

126.

Wisniewski

, Boutajangout

(2010) Vaccination as a therapeutic approach to Alzheimer’s disease. Mt Sinai J Med 77, 17–31.

127.

Chai

, Wu

, Murray

, Kinley

, Cella

, Sims

, Buckner

, Hanmer

, Davies

, O’Neill

, Hutton

, Citron

(2011) Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of Tau pathology and delay of disease progression. J Biol Chem 286, 34457–34467.

128.

, Sigurdsson

(2011) Immunotherapy for tauopathies. J Mol Neurosci 45, 690–695.

129.

Troquier

, Caillierez

, Burnouf

, Fernandez-Gomez

, Grosjean

, Zommer

, Sergeant

, Schraen-Maschke

, Blum

, Buee

(2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: A suitable therapeutic approach. Curr Alzheimer Res 9, 397–405.

130.

Theunis

, Crespo-Biel

, Gafner

, Pihlgren

, Lopez-Deber

, Reis

, Hickman

, Adolfsson

, Chuard

, Ndao

, Borghgraef

, Devijver

, Van Leuven

, Pfeifer

, Muhs

(2013) Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PLoS One 8, e72301.

131.

Umeda

, Eguchi

, Kunori

, Matsumoto

, Taniguchi

, Mori

, Tomiyama

(2015) Passive immunotherapy of tauopathy targeting pSer413-tau: A pilot study in mice. Ann Clin Transl Neurol 2, 241–255.

132.

Sankaranarayanan

, Barten

, Vana

, Devidze

, Yang

, Cadelina

, Hoque

, DeCarr

, Keenan

, Lin

, Cao

, Snyder

, Zhang

, Nitla

, Hirschfeld

, Barrezueta

, Polson

, Wes

, Rangan

, Cacace

, Albright

, Meredith

Jr , Trojanowski

, Lee

, Brunden

, Ahlijanian

(2015) Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 10, e0125614.

133.

d’Abramo

, Acker

, Jimenez

, Davies

(2013) Tau passive immunotherapy in mutant P301L mice: Antibody affinity versus specificity. PLoS One 8, e62402.

134.

Castillo-Carranza

, Sengupta

, Guerrero-Munoz

, Lasagna-Reeves

, Gerson

, Singh

, Estes

, Barrett

, Dineley

, Jackson

, Kayed

(2014) Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34, 4260–4272.

135.

Castillo-Carranza

, Guerrero-Munoz

, Sengupta

, Hernandez

, Barrett

, Dineley

, Kayed

(2015) Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer’s disease mouse model. J Neurosci 35, 4857–4868.

136.

Burre

, Sharma

, Sudhof

(2014) alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci U S A 111, E4274–4283.

137.

Uéda

, Fukushima

, Masliah

, Xia

, Iwai

, Yoshimoto

, Otero

, Kondo

, Ihara

, Saitoh

(1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90, 11282–11286.

138.

Masliah

, Iwai

, Mallory

, Ueda

, Saitoh

(1996) Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer’s disease. Am J Pathol 148, 201–210.

139.

Goedert

, Jakes

, Spillantini

(2017) The synucleinopathies: Twenty years on. J Parkinsons Dis 7, S53–S71.

140.

Tsigelny

, Bar-On

, Sharikov

, Crews

, Hashimoto

, Miller

, Keller

, Platoshyn

, Yuan

, Masliah

(2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J 274, 1862–1877.

141.

Masliah

, Rockenstein

, Adame

, Alford

, Crews

, Hashimoto

, Seubert

, Lee

, Goldstein

, Chilcote

, Games

, Schenk

(2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 46, 857–868.

142.

Masliah

, Rockenstein

, Mante

, Crews

, Spencer

, Adame

, Patrick

, Trejo

, Ubhi

, Rohn

, Mueller-Steiner

, Seubert

, Barbour

, McConlogue

, Buttini

, Games

, Schenk

(2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PloS One 6, e19338.

143.

Games

, Valera

, Spencer

, Rockenstein

, Mante

, Adame

, Patrick

, Ubhi

, Nuber

, Sacayon

, Zago

, Seubert

, Barbour

, Schenk

, Masliah

(2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci 34, 9441–9454.

144.

Tran

, Chung

, Iba

, Zhang

, Trojanowski

, Luk

, Lee

(2014) Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep 7, 2054–2065.

145.

Shahaduzzaman

, Nash

, Hudson

, Sharif

, Grimmig

, Lin

, Bai

, Liu

, Ugen

, Cao

, Bickford

(2015) Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson’s disease. PLoS One 10, e0116841.

146.

Spencer

, Emadi

, Desplats

, Eleuteri

, Michael

, Kosberg

, Shen

, Rockenstein

, Patrick

, Adame

, Gonzalez

, Sierks

, Masliah

(2014) ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 22, 1753–1767.

147.

Emadi

, Liu

, Yuan

, Schulz

, McAllister

, Lyubchenko

, Messer

, Sierks

(2004) Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43, 2871–2878.

148.

Emadi

, Barkhordarian

, Wang

, Schulz

, Sierks

(2007) Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 368, 1132–1144.

149.

Bousset

, Pieri

, Ruiz-Arlandis

, Gath

, Jensen

, Habenstein

, Madiona

, Olieric

, Bockmann

, Meier

, Melki

(2013) Structural and functional characterization of two alpha-synuclein strains. Nat Commun 4, 2575.

150.

Zhou

, Emadi

, Sierks

, Messer

(2004) A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 10, 1023–1031.

151.

Lynch

, Zhou

, Messer

(2008) An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 377, 136–147.

152.

Joshi

, Butler

, Messer

(2012) Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. MAbs 4, 686–693.

153.

Näsström

, Gonçalves

, Sahlin

, Nordström

, Screpanti Sundquist

, Lannfelt

, Bergström

, Outeiro

, Ingelsson

(2011) Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS One 6, e27230.

154.

Lindstrom

, Fagerqvist

, Nordstrom

, Eriksson

, Lord

, Tucker

, Andersson

, Johannesson

, Schell

, Kahle

, Moller

, Gellerfors

, Bergstrom

, Lannfelt

, Ingelsson

(2014) Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice. Neurobiol Dis 69, 134–143.

155.

Valera

, Spencer

, Fields

, Trinh

, Adame

, Mante

, Rockenstein

, Desplats

, Masliah

(2017) Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun 5, 2.